Pfizer Sings Lyrica's Praises In Beating Earnings Guidance
This article was originally published in The Pink Sheet Daily
Executive Summary
Company beats recent lowered earnings guidance as a result of strong performance in its human health division as well as faster-than-anticipated cost savings from restructuring program.